BAP1 and neoplasm: Thus, identification and targeting of tumour-specific epigenetic dysregulations represent a possible therapeutic approach via administration of epidrugs as EZH2 (inhibitors of histone methyltransferase, core component of PRC2 complex), DNMT (DNA Methyltransferase), HDAC (Histone deacetylase) and BAP1 inhibitors [18, 29–31].